How does Gilead Sciences' oncology business perform?

Gilead's oncology revenue fell 3% year-over-year in the third quarter, but the company has a large and active oncology pipeline that is expected to drive future growth.

What is Scotiabank's view on the biopharma sector?

Scotiabank analyst Louise Chen has an "out-of-consensus" positive view on the biopharma sector, seeing an attractive entry point before the next wave of innovation.

Home / Business and Economy / Gilead Sciences Shines as Dividend Champ Amid Biopharma Slump

Gilead Sciences Shines as Dividend Champ Amid Biopharma Slump

Q: What is Gilead Sciences' performance in the stock market?

Gilead Sciences' shares have climbed more than 36% since the beginning of 2025, outperforming the broader market.

17 Nov

•

Summary

Gilead Sciences' shares climb over 36% since 2025
Oncology revenue falls 3% in Q3, but pipeline remains robust
Scotiabank analyst sees opportunity in undervalued biopharma stocks

Gilead Sciences Shines as Dividend Champ Amid Biopharma Slump

As of November 17, 2025, Gilead Sciences, Inc. (NASDAQ:GILD) has proven to be a standout performer in the biopharma industry. The company's shares have climbed more than 36% since the beginning of 2025, outpacing the broader market. This strong performance is largely attributed to Gilead's status as a dependable dividend payer, a trait that has made it one of the 15 Best Passive Income Stocks to Buy Right Now.

In a recent report, Scotiabank analyst Louise Chen highlighted an "out-of-consensus" positive view on the biopharma sector, noting that years of underperformance in large-cap biopharma stocks could present an attractive entry point before the next wave of innovation. Chen maintained her Outperform rating on Gilead Sciences, recognizing the company's potential.